Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056446 · ClinicalTrials.gov registry record · Phase 3
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 855
- Enrollment target
NCT00056446 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 855 participants.
The verdict
NCT00056446, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 855 participants
- Enrollment target
Study Summary
The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.
Interventions
- DRUG Vatalanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 855 participants |
| Start Date | 2003-01 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056446
The ClinicalTrials.gov registry entry for NCT00056446 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 855 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vatalanib is the first listed.
NCT00056446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056446 about?
NCT00056446 is a clinical study titled "Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer". The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.
What is the current status of trial NCT00056446?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 855 participants. The study started on 2003-01. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00056446?
The interventions under investigation include: Vatalanib (DRUG).
Who is sponsoring clinical trial NCT00056446?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.